Log In

Bispecific antibody platforms for cancer immunotherapy

Files

Access status: Embargo until 2050-01-01 , bispecific.pdf (1.54 MB)
How and where to find an Open Access version of this publication?

Publication date

2014

Authors

Lameris, R.
de Bruin, Renée C GISNI 000000039070859X
Schneiders, F.L.
van Bergen En Henegouwen, Paul M PORCID 0000-0001-6050-9042ISNI 0000000387765753
Verheul, H.M.
de Gruijl, T.D.
van der Vliet, H.J.

Editors

Advisors

Supervisors

DOI

https://doi.org/10.1016/j.critrevonc.2014.08.003

Document Type

Article

Metadata

Show full item record

Collections

Utrecht University Repository
Open Access logo

License

Abstract

165AbstractOver the past decades advances in bioengineering and expanded insight in tumor immunology have resulted in the emergence of novelbispecific antibody (bsAb) constructs that are capable of redirecting immune effector cells to the tumor microenvironment. (Pre-) clinicalstudies of various bsAb constructs have shown impressive results in terms of immune effector cell retargeting, target dependent activation and the induction of anti-tumor responses. This review summarizes recent advances in the field of bsAb-therapy and limitations that wereencountered. Furthermore, we will discuss potential future developments that can be expected to take the bsAb approach successfully forward.

Keywords

Bi-specific antibodies, Dual specific retargeting, Immune effector cells, Anti-cancer therapy, SDG 3 - Good Health and Well-being

Citation

Lameris, R, de Bruin, R, Schneiders, F L, van Bergen en Henegouwen, P, Verheul, H M, de Gruijl, T D & van der Vliet, H J 2014, 'Bispecific antibody platforms for cancer immunotherapy', Critical Reviews in Oncology Hematology, vol. 92, pp. 153-165. https://doi.org/10.1016/j.critrevonc.2014.08.003

URI

http://hdl.handle.net/1874/307335